📰 Editha Perez News
Editha Perez News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Editha Perez. Real-time updates on events, politics, business and more.
October 23, 2023
Updated safety data supports the selection of 20 mg/kg q2w as the recommended Phase 2 dose Improved efficacy with one partial response improving to a complete response , two additional patients with...
October 17, 2023
BDC-3042, a novel Dectin-2 agonistic antibody that stimulates the innate immune system, is being evaluated in a Phase 1/2 dose-escalation and expansion study in patients with a broad range of solid...
October 16, 2023
REDWOOD CITY, Calif., Oct. 16, 2023 -- Bolt Biotherapeutics, Inc. , a clinical-stage biopharmaceutical company pioneering novel immuno-oncology therapeutics for the treatment of cancer, today...
October 2, 2023
The FDA has given an orphan drug designation to BDC-1001 for the treatment of patients with gastric cancers, including gastroesophageal junction cancer.
August 11, 2023
The first patients have been dosed in the phase 2 portion of a phase 1/2 trial evaluating BDC-1001 monotherapy in patients with HER2-positive colorectal cancer, endometrial cancer, and gastroesophageal cancer.
August 3, 2023
BDC-1001 is a Boltbody™ Immune-Stimulating Antibody Conjugate in development for HER2-positive breast, colorectal, endometrial, and gastroesophageal cancersBDC-1001 administered to initial patients...
May 25, 2023
Treatment with BDC-1001 at the recommended Phase 2 dose resulted in 29% objective response rate in evaluable patients with HER2-positive tumors, in both monotherapy and in combination with... | May 25, 2023
March 30, 2023
BDC-1001 monotherapy and in combination with nivolumab generated antitumor activity with acceptable tolerability in patients with advanced HER2-expressing solid tumors, according to topline data from the dose-escalation portion of a phase 1 trial.
March 29, 2023
BDC-1001 elicited objective clinical responses, including multiple PRs and long-term stable disease, across a diverse set of solid tumor types in monotherapy and in combination with... | March 29, 2023
March 29, 2023
BDC-1001 elicited objective clinical responses, including multiple PRs and long-term stable disease, across a diverse set of solid tumor types in monotherapy and in combination with nivolumabData support selection of a recommended Phase 2 dose and advance...